Publications by authors named "A Blauz"

Article Synopsis
  • Kinesin-5 inhibitors provide a targeted cancer treatment option, reducing harmful side effects commonly associated with other anti-cancer drugs.
  • The study focused on modifying the kinesin-5 inhibitor CPUYL064 by adding a ferrocenyl group, creating organometallic hybrids.
  • These modified compounds demonstrated significantly improved effectiveness against cancer cells, with some showing up to 19 times greater activity due to the ferrocenyl addition.*
View Article and Find Full Text PDF

Synthesis and biological activity of two series of modified side chain methotrexate (MTX) derivatives are presented, one with a ferrocenyl moiety inserted between the pteroyl and glutamate portions of the molecule and the other with glutamate substituted for short chain amino acids. Ferrocenyl derivatives of MTX turned out to be rather moderate inhibitors of dihydrofolate reductase (DHFR) although molecular modeling suggested more effective interactions between these compounds and the target enzyme. More interestingly, ferrocene-decorated MTX derivatives were able to impede the proliferation of four murine and human cell lines as well as their methotrexate-resistant counterparts, overcoming the multidrug resistance (MDR) barrier.

View Article and Find Full Text PDF

Mitoxantrone resistant variant of SW620 line was developed, characterized and subsequently used as a model system to determine oncostatin M ability to modulate MDR phenomenon. The selection regimen allowed for overexpression of ABCG2 and ABCB1 both at the RNA and protein level, which was further confirmed by functional assays. Oncostatin M supplementation resulted in partial reversal of MDR phenotype by decreasing overexpression of ABCG2 demonstrating for the first time the ability of this cytokine for selective down-regulation of one of MDR proteins.

View Article and Find Full Text PDF
Article Synopsis
  • * These conjugates demonstrated a significant increase in cytotoxicity—up to 36 times—especially against drug-resistant cancer cells, affecting how cells progress through the cell cycle by causing mitotic arrest.
  • * Although ruthenium derivatives produced reactive oxygen species (ROS), the metal complex did not significantly impact KSP inhibition, indicating that the combination alters the inhibitor's mechanism of action.
View Article and Find Full Text PDF

Antimitotic agents are among the most important drugs used in anticancer therapy. Kinesin spindle protein (KSP) was proposed as a promising target for new antimitotic drugs. Herein, we report the synthesis of Ru, Os, Rh, and Ir half-sandwich complexes with the KSP inhibitor ispinesib and its ()-enantiomer.

View Article and Find Full Text PDF